AboutPortfolioInvestment FocusLeadershipInsightsContact Partner With Us
News & Insights

Latest from
MedLinks Capital

Perspectives on healthcare investment, industry trends, portfolio milestones, and the ideas shaping the future of life sciences.

All Articles

Recent Publications

Investment News
MedLinks Capital's Portfolio Achieves Multiple Regulatory Milestones Across Breakthrough Programs
From FDA RMAT designation for Gradalis to FDA Breakthrough Device status for Virtuoso Surgical, our active portfolio continues to validate our conviction-based investment thesis in precision medicine and surgical innovation.
May 20264 min read
Read Full Story
Portfolio News
Gradalis Receives FDA RMAT Designation for Personalised Cancer Immunotherapy
The FDA's Regenerative Medicine Advanced Therapy designation marks a landmark milestone for Gradalis and validates the potential of next-generation personalised immunotherapy in oncology.
April 20263 min read
Read Full Story
Portfolio News
Virtuoso Surgical Receives FDA Breakthrough Device Designation for Robotic Platform
The FDA Breakthrough Device designation accelerates Virtuoso Surgical's path to market for its next-generation robotic platform designed to expand the reach of minimally invasive surgery.
March 20263 min read
Read Full Story
Portfolio News
Lobe Sciences Advances L-130 Non-Hallucinogenic Psilocin Therapy into Clinical Trials
Lobe Sciences' proprietary L-130 compound, targeting cluster headaches, PTSD, TBI, and rare neurological conditions, advances with a patent estate extending beyond 2040 and orphan drug pathway eligibility.
February 20264 min read
Read Full Story
Industry Insight
A Legacy of Value Creation: From KCI to Gradalis — The MedLinks Investment Thesis
How decades of building category-defining healthcare companies — from a 12,882x MOIC on KCI to a $4B Fresenius acquisition of Renal Care Group — inform our approach to today's breakthrough pipeline.
January 20266 min read
Read Full Story
Portfolio News
CNS Biosciences Progresses Irminix® in Phase 2 for Rare Neurodegenerative Conditions
Emeramide (Irminix®) continues its Phase 2 programme targeting Progressive Supranuclear Palsy and Parkinson's disease, advancing CNS Biosciences' mission to address critical unmet needs in rare neurological disease.
December 20253 min read
Read Full Story
Newsletter

Stay Informed

Subscribe to the MedLinks Capital newsletter for our latest investment insights, portfolio news, and healthcare market perspectives — delivered to your inbox monthly.